Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...
IPO
TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board
China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main...
Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline
China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...
China’s WeiMai Plans Hong Kong IPO to Expand AI-Powered Healthcare Services
China-based WeiMai Inc. plans to make an initial public offering (IPO) to the Hong Kong...
AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange
AstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot is exploring plans to move the British pharmaceutical...
Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation
Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology...
BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline
Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...
Diagens Biotech’s AI Imaging Platform iMedImage Makes Hong Kong IPO Debut
China-based Hangzhou Diagens Biotechnology Co., Ltd. has filed for an initial public offering (IPO) with...
GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success
China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the...
Immvira Bioscience Files for Hong Kong IPO to Advance Oncolytic Immunotherapy Pipeline
Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong...
Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. has successfully completed an initial public offering (IPO) of...
Medtide’s IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services
Hangzhou-based Medtide Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides,...
EpimAb Biotherapeutics Submits Hong Kong IPO Application as Biotech Expands
Shanghai-based biotech EpimAb Biotherapeutics, Inc. has submitted a main board listing application to the Hong...
Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline
Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...
CF PharmTech Files for Hong Kong IPO to Expand Respiratory Disease Treatments
China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for...
Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development
Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...
Bayzed Health Launches HK IPO to Expand Cancer Care Services
China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...
TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share
China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...
Innogen Pharma Resubmits Hong Kong IPO Application With Promising Diabetes Drug
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. has resubmitted its application for a main board...
Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress
China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune...